Advertisement

Toxic Shock Syndromes

  • K. B. Laupland
  • H. Dele Davies
Chapter
  • 1.7k Downloads

Abstract

Staphylococcal toxic shock syndrome (TSS) was first described in seven children aged 8–17 years by Todd et al. in 1978 [1]. It shortly thereafter became well known as an illness of menstruating women who used tampons [2, 3]. The syndrome is characterized by rapid onset of fever, hypotension, and multisystem failure with desquamating rash occurring in convalescence [4]. The majority of early cases reported were menstrually associated (MTSS) but this has been changing with an increasing proportion of cases non-menstrually associated (NMTSS) [5].

Keywords

Kawasaki Disease Necrotizing Fasciitis Toxic Shock Syndrome Staphylococcal Enterotoxin Invasive Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Todd J, Fishaut M, Kapral F, Welch T (1978) Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 2(8100):1116–1118CrossRefPubMedGoogle Scholar
  2. 2.
    Davis JP, Chesney PJ, Wand PJ, LaVenture M (1980) Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 303(25):1429–1435PubMedGoogle Scholar
  3. 3.
    Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, Anderson RL, Hill DL, Broome CV, Band JD, et al. (1980) Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 303(25):1436–1442PubMedCrossRefGoogle Scholar
  4. 4.
    Wharton M, Chorba TL, Vogt RL, Morse DL, Buehler JW (1990) Case definitions for public health surveillance. MMWR Recomm Rep 39(RR-13):1–43PubMedGoogle Scholar
  5. 5.
    Kain KC, Schulzer M, Chow AW (1993) Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 16(1):100–106PubMedGoogle Scholar
  6. 6.
    Cone LA, Woodard DR, Schlievert PM, Tomory GS (1987) Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 317(3):146–149PubMedCrossRefGoogle Scholar
  7. 7.
    Bartter T, Dascal A, Carroll K, Curley FJ (1988) ‘Toxic strep syndrome’. A manifestation of group A streptococcal infection. Arch Intern Med 148(6):1421–1424CrossRefPubMedGoogle Scholar
  8. 8.
    Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, Kaplan E (1989) Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 321(1):1–7PubMedCrossRefGoogle Scholar
  9. 9.
    The Working Group on Severe Streptococcal Infections (1993) Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA 269(3):390–391CrossRefGoogle Scholar
  10. 10.
    Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE, Low DE (1996) Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 335(8):547–554CrossRefPubMedGoogle Scholar
  11. 11.
    Hoge CW, Schwartz B, Talkington DF, Breiman RF, Mac-Neill EM, Englender SJ (1993) The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. JAMA 269(3):384–389CrossRefPubMedGoogle Scholar
  12. 12.
    Zurawski CA, Bardsley M, Beall B, Elliott JA, Facklam R, Schwartz B, Farley MM (1998) Invasive group A streptococcal disease in metropolitan Atlanta: a population-based assessment. Clin Infect Dis 27(1):150–157CrossRefPubMedGoogle Scholar
  13. 13.
    Laupland KB, Davies HD, Low DE, Schwartz B, Green K, McGeer A (2000) Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Ontario Group A Streptococcal Study Group. Pediatrics 105(5):E60CrossRefPubMedGoogle Scholar
  14. 14.
    Schuchat A, Broome CV (1991) Toxic shock syndrome and tampons. Epidemiol Rev 13:99–112PubMedGoogle Scholar
  15. 15.
    Kaul R, McGeer A, Low DE, Green K, Schwartz B (1997) Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med 103(1):18–24CrossRefPubMedGoogle Scholar
  16. 16.
    Schlech WF, 3rd, Shands KN, Reingold AL, Dan BB, Schmid GP, Hargrett NT, Hightower A, Herwaldt LA, Neill MA, Band JD, et al. (1982) Risk factors for development of toxic shock syndrome. Association with a tampon brand. JAMA 248(7):835–839CrossRefPubMedGoogle Scholar
  17. 17.
    Osterholm MT, Davis JP, Gibson RW, Mandel JS, Wintermeyer LA, Helms CM, Forfang JC, Rondeau J, Vergeront JM (1982) Tri-state toxic-state syndrome study. I. Epidemiologic findings. J Infect Dis 145(4):431–440PubMedGoogle Scholar
  18. 18.
    Schwartz B, Gaventa S, Broome CV, Reingold AL, Hightower AW, Perlman JA, Wolf PH (1989) Nonmenstrual toxic shock syndrome associated with barrier contraceptives: report of a case-control study. Rev Infect Dis 11Suppl 1:S43–48; discussion S48–49PubMedGoogle Scholar
  19. 19.
    Gaventa S, Reingold AL, Hightower AW, Broome CV, Schwartz B, Hoppe C, Harwell J, Lefkowitz LK, Makintubee S, Cundiff DR, et al. (1989) Active surveillance for toxic shock syndrome in the United States, 1986. Rev Infect Dis 11Suppl 1:S28–34PubMedGoogle Scholar
  20. 20.
    Osterholm MT, Forfang JC (1982) Toxic-shock syndrome in Minnesota: results of an active-passive surveillance system. J Infect Dis 145(4):458–464PubMedGoogle Scholar
  21. 21.
    Latham RH, Kehrberg MW, Jacobson JA, Smith CB (1982) Toxic shock syndrome in Utah: a case-control and surveillance study. Ann Intern Med 96(6):906–908PubMedGoogle Scholar
  22. 22.
    Davis JP, Osterholm MT, Helms CM, Vergeront JM, Wintermeyer LA, Forfang JC, Judy LA, Rondeau J, Schell WL (1982) Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings. J Infect Dis 145(4):441–448PubMedGoogle Scholar
  23. 23.
    Chesney PJ, Davis JP, Purdy WK, Wand PJ, Chesney RW (1981) Clinical manifestations of toxic shock syndrome. JAMA 246(7):741–748CrossRefPubMedGoogle Scholar
  24. 24.
    Schlievert PM, Tripp TJ, Peterson ML (2004) Reemergence of staphylococcal toxic shock syndrome in Minneapolis-St. Paul, Minnesota, during the 2000–2003 surveillance period. J Clin Microbiol 42(6):2875–2876CrossRefPubMedGoogle Scholar
  25. 25.
    Tierno PM, Jr (2005) Reemergence of staphylococcal toxic shock syndrome in the United States since 2000. J Clin Microbiol 43(4):2032; author reply 2032–2033CrossRefPubMedGoogle Scholar
  26. 26.
    Broome CV (1989) Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis 11Suppl 1:S14–21PubMedGoogle Scholar
  27. 27.
    Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5(11):685–694CrossRefPubMedGoogle Scholar
  28. 28.
    O’Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM, Danila R, Zell ER, Facklam R, Schwartz B, et al. (2002) Epidemiology of invasive group a streptococcus disease in the United States, 1995–1999. Clin Infect Dis 35(3):268–276CrossRefPubMedGoogle Scholar
  29. 29.
    Eriksson BK, Andersson J, Holm SE, Norgren M (1998) Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. Clin Infect Dis 27(6):1428–1436CrossRefPubMedGoogle Scholar
  30. 30.
    Ekelund K, Skinhoj P, Madsen J, Konradsen HB (2005) Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects. Clin Microbiol Infect 11(7):569–576CrossRefPubMedGoogle Scholar
  31. 31.
    Kum WW, Laupland KB, See RH, Chow AW (1993) Improved purification and biologic activities of staphylococcal toxic shock syndrome toxin 1. J Clin Microbiol 31(10):2654–2660PubMedGoogle Scholar
  32. 32.
    Parsonnet J, Gillis ZA, Richter AG, Pier GB (1987) A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun 55(5):1070–1076PubMedGoogle Scholar
  33. 33.
    Garbe PL, Arko RJ, Reingold AL, Graves LM, Hayes PS, Hightower AW, Chandler FW, Broome CV (1985) Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins. JAMA 253(17):2538–2542CrossRefPubMedGoogle Scholar
  34. 34.
    Bergdoll MS, Crass BA, Reiser RF, Robbins RN, Davis JP (1981) A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet 1(8228):1017–1021CrossRefPubMedGoogle Scholar
  35. 35.
    Schlievert PM, Shands KN, Dan BB, Schmid GP, Nishimura RD (1981) Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis 143(4):509–516PubMedGoogle Scholar
  36. 36.
    Crass BA, Bergdoll MS (1986) Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. J Clin Microbiol 23(6):1138–1139PubMedGoogle Scholar
  37. 37.
    Lee VT, Chang AH, Chow AW (1992) Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)-and non-TSS-associated Staphylococcus aureus isolates. J Infect Dis 166(4):911–915PubMedGoogle Scholar
  38. 38.
    Schlievert PM (1986) Staphylococcal enterotoxin B and toxic-shock syndrome toxin-1 are significantly associated with non-menstrual TSS. Lancet 1(8490):1149–1150CrossRefPubMedGoogle Scholar
  39. 39.
    Hayes PS, Graves LM, Feeley JC, Hancock GA, Cohen ML, Reingold AL, Broome CV, Hightower AW (1984) Production of toxic-shock-associated protein(s) in Staphylococcus aureus strains isolated from 1956 through 1982. J Clin Microbiol 20(1):43–46PubMedGoogle Scholar
  40. 40.
    Schlievert PM, Blomster DA (1983) Production of staphylococcal pyrogenic exotoxin type C: influence of physical and chemical factors. J Infect Dis 147(2):236–242PubMedGoogle Scholar
  41. 41.
    Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL, et al. (2005) Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women. J Clin Microbiol 43(9):4628–4634CrossRefPubMedGoogle Scholar
  42. 42.
    Musser JM, Schlievert PM, Chow AW, Ewan P, Kreiswirth BN, Rosdahl VT, Naidu AS, Witte W, Selander RK (1990) A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome. Proc Natl Acad Sci U S A 87(1):225–229CrossRefPubMedGoogle Scholar
  43. 43.
    Marrack P, Kappler J (1990) The staphylococcal enterotoxins and their relatives. Science 248(4959):1066PubMedGoogle Scholar
  44. 44.
    Proft T, Fraser JD (2003) Bacterial superantigens. Clin Exp Immunol 133(3):299–306CrossRefPubMedGoogle Scholar
  45. 45.
    Llewelyn M, Cohen J (2002) Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2(3):156–162CrossRefPubMedGoogle Scholar
  46. 46.
    Kum WW, Laupland KB, Chow AW (2000) Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality. Can J Microbiol 46(2):171–179CrossRefPubMedGoogle Scholar
  47. 47.
    Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, Marrack P, Kotzin BL (1990) Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 172(3):981–984CrossRefPubMedGoogle Scholar
  48. 48.
    Cockerill FR, 3rd, MacDonald KL, Thompson RL, Roberson F, Kohner PC, Besser-Wiek J, Manahan JM, Musser JM, Schlievert PM, Talbot J, et al. (1997) An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 277(1):38–43CrossRefPubMedGoogle Scholar
  49. 49.
    Bisno AL, Brito MO, Collins CM (2003) Molecular basis of group A streptococcal virulence. Lancet Infect Dis 3(4):191–200CrossRefPubMedGoogle Scholar
  50. 50.
    Talkington DF, Schwartz B, Black CM, Todd JK, Elliott J, Breiman RF, Facklam RR (1993) Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun 61(8):3369–3374PubMedGoogle Scholar
  51. 51.
    Hauser AR, Stevens DL, Kaplan EL, Schlievert PM (1991) Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 29(8):1562–1567PubMedGoogle Scholar
  52. 52.
    Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK (1991) Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci U S A 88(7):2668–2672CrossRefPubMedGoogle Scholar
  53. 53.
    Yutsudo T, Murai H, Gonzalez J, Takao T, Shimonishi Y, Takeda Y, Igarashi H, Hinuma Y (1992) A new type of mitogenic factor produced by Streptococcus pyogenes. FEBS Lett 308(1):30–34CrossRefPubMedGoogle Scholar
  54. 54.
    Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR (1993) A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest 92(2):710–719CrossRefPubMedGoogle Scholar
  55. 55.
    Watanabe-Ohnishi R, Low DE, McGeer A, Stevens DL, Schlievert PM, Newton D, Schwartz B, Kreiswirth B, Kotb M (1995) Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis 171(1):74–84PubMedGoogle Scholar
  56. 56.
    Paris AL, Herwaldt LA, Blum D, Schmid GP, Shands KN, Broome CV (1982) Pathologic findings in twelve fatal cases of toxic shock syndrome. Ann Intern Med 96(6):852–857PubMedGoogle Scholar
  57. 57.
    Larkin SM, Williams DN, Osterholm MT, Tofte RW, Posalaky Z (1982) Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases. Ann Intern Med 96(6):858–864PubMedGoogle Scholar
  58. 58.
    Forni AL, Kaplan EL, Schlievert PM, Roberts RB (1995) Clinical and microbiological characteristics of severe group A streptococcus infections and streptococcal toxic shock syndrome. Clin Infect Dis 21(2):333–340PubMedGoogle Scholar
  59. 59.
    Chesney RW, Chesney PJ, Davis JP, Segar WE (1981) Renal manifestations of the staphylococcal toxic-shock syndrome. Am J Med 71(4):583–588CrossRefPubMedGoogle Scholar
  60. 60.
    Demeter SL, Fuenning C, Klein JJ (1982) Pleural effusion in toxic shock syndrome. Ann Intern Med 97(1):148–149PubMedGoogle Scholar
  61. 61.
    Rosene KA, Copass MK, Kastner LS, Nolan CM, Eschenbach DA (1982) Persistent neuropsychological sequelae of toxic shock syndrome. Ann Intern Med 96(6):865–870PubMedGoogle Scholar
  62. 62.
    Stamenkovic I, Lew PD (1984) Early recognition of potentially fatal necrotizing fasciitis. The use of frozen-section biopsy. N Engl J Med 310(26):1689–1693PubMedCrossRefGoogle Scholar
  63. 63.
    Laupland KB, Dele Davies H (1999) Epidemiology, etiology, and management of Kawasaki disease: state of the art. Pediatr Cardiol 20(3):177–183CrossRefPubMedGoogle Scholar
  64. 64.
    Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30(4):536–555CrossRefPubMedGoogle Scholar
  65. 65.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19):1368–1377CrossRefPubMedGoogle Scholar
  66. 66.
    Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 342(18):1301–1308Google Scholar
  67. 67.
    Kress JP, Pohlman AS, O’Connor MF, Hall JB (2000) Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 342(20):1471–1477CrossRefPubMedGoogle Scholar
  68. 68.
    Schiffl H, Lang SM, Fischer R (2002) Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 346(5):305–310CrossRefPubMedGoogle Scholar
  69. 69.
    van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345(19):1359–1367CrossRefPubMedGoogle Scholar
  70. 70.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10):699–709CrossRefPubMedGoogle Scholar
  71. 71.
    Doig CJ, Laupland KB, Zygun DA, Manns BJ (2003) The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C. Expert Opin Pharmacother 4(10):1789–1799CrossRefPubMedGoogle Scholar
  72. 72.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7):862–871CrossRefPubMedGoogle Scholar
  73. 73.
    Chesney PJ, Crass BA, Polyak MB, Wand PJ, Warner TF, Vergeront JM, Davis JP, Tofte RW, Chesney RW, Bergdoll MS (1982) Toxic shock syndrome: management and long-term sequelae. Ann Intern Med 96(6):847–851PubMedGoogle Scholar
  74. 74.
    Eagle H (1952) Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 13(4):389–399CrossRefPubMedGoogle Scholar
  75. 75.
    Tanaka M, Hasegawa T, Okamoto A, Torii K, Ohta M (2005) Effect of antibiotics on group A Streptococcus exoprotein production analyzed by two-dimensional gel electrophoresis. Antimicrob Agents Chemother 49(1):88–96CrossRefPubMedGoogle Scholar
  76. 76.
    Stevens DL, Gibbons AE, Bergstrom R, Winn V (1988) The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 158(1):23–28PubMedGoogle Scholar
  77. 77.
    Laupland KB, Boucher P, Rotstein C, Cook DJ, Doig CJ (2004) Intravenous immunoglobulin for severe infections: a survey of Canadian specialists. J Crit Care 19(2):75–81CrossRefPubMedGoogle Scholar
  78. 78.
    Norrby-Teglund A, Ihendyane N, Darenberg J (2003) Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 35(9):683–689CrossRefPubMedGoogle Scholar
  79. 79.
    Takei S, Arora YK, Walker SM (1993) Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest 91(2):602–607CrossRefPubMedGoogle Scholar
  80. 80.
    Skansen-Saphir U, Andersson J, Bjork L, Andersson U (1994) Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 24(4):916–922CrossRefPubMedGoogle Scholar
  81. 81.
    Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O’Rourke K, Talbot J, Low DE (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome — a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 28(4):800–807CrossRefPubMedGoogle Scholar
  82. 82.
    Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37(3):333–340CrossRefPubMedGoogle Scholar
  83. 83.
    Durongpisitkul K, Gururaj VJ, Park JM, Martin CF (1995) The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 96(6):1057–1061PubMedGoogle Scholar
  84. 84.
    Laupland KB, Conly JM (2003) Treatment of Staphylococcus aureus colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. Clin Infect Dis 37(7):933–938CrossRefPubMedGoogle Scholar
  85. 85.
    Centers for Disease Control and Prevention (2002) Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. Clin Infect Dis 35(8):950–959CrossRefGoogle Scholar
  86. 86.
    Smith A, Lamagni TL, Oliver I, Efstratiou A, George RC, Stuart JM (2005) Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis? Lancet Infect Dis 5(8):494–500CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2007

Authors and Affiliations

  • K. B. Laupland
    • 1
  • H. Dele Davies
    • 2
  1. 1.Departments of Medicine and Critical Care MedicineUniversity of CalgaryCalgaryCanada
  2. 2.Departments of Pediatrics and Human DevelopmentMichigan State University, College of Human MedicineEast LansingUSA

Personalised recommendations